Our Mission

To combine bioengineering with systems medicine to better understand disease origins and mechanisms, leading to the discovery of new drugs and biomarkers, and the development of advanced devices for improving diagnosis and treatment, especially for cancer, neurological, and metabolic disorders.

Our systems medicine research provides new avenues to understand the causes of diseases, identify biomarkers, discover therapeutic targets, and attain precision in disease management.

Our work at Houston Methodist has led to clinical trials among all our research areas. We are also training a new generation of physicians and scientists to use systems approaches to medicine.

Research Projects

  • Cancer
  • Alzheimer’s Disease and Related Disorders
  • Label-free Imaging-Guided Theragnostics
  • Cancer

    Cancer

    C1. Brain tumor

    C1.1:  Tumor-astrocyte crosstalk regulating brain metastatic cancer. (NIH R01CA238727)
    C1.2:  Development of new PCDH7 single domain antibody therapy for brain mets. (Chao Foundation)
    C1.3:  Mechanism and drug target of Alzheimer’s suppression of brain tumor. (NIH R01CA238727-S1; Chao Foundation)
    C1.4:  Mechanism and drug repositioning of digoxin for medulloblastoma group III/IV. (Chao Foundation; Clinical Trial)
    C1.5:  Chronic stress and brain metastasis from triple-negative breast Cancer. (Chao and Dunn Foundations)
    C1.6:  Prognostic gene discovery in glioblastoma patients (Dunn Foundation, Greg and Lily Nelson Fund)


    C2. Ovarian cancer

    C2.1:  Inter-cellular exosomal communication of high grade serous ovarian cancer. (Chao Foundation)
    C2.2:  Prognostic biomarkers of high grade serous ovarian cancer. (Tina’s Wish Foundation, CPRIT CCBTP)
    C2.3:  MFAP5 immunotherapy for ovarian cancer. (Carole Walter Looke Fund and Chao Foundation)
    C2.4:  Immune checkpoint regulator in ovarian cancer progression. (DOD W81XWH-17-1-0126; Dunn Foundation)
    C2.5:  Platelets promote growth of ovarian cancer. (NIH R01CA177909)


    C3. Lung Disease

    C3.1:  Immuno-radiotherapy crosstalk for non-small cell lung cancer. (Chao and Dunn Foundations)
    C3.2:  Immunotherapy for idiopathic pulmonary fibrosis. (Chao and Dunn Foundations)
    C3.3:  Cancer risk assessment of incidental lung nodules (Chao and Dunn Foundations)


    C4. Bone Cancer

    C4.1.  Spatiotemporal modeling of cancer-niche interactions in bone metastasis. (NIH U01CA253553)

    C4.2.  Drug combinations and mechanism of metformin and imatinib for Ewing sarcoma. (Dunn Foundation)


    C5. Breast Cancer

    C5.1. Epithelial-mesenchymal transition in breast tumor metastasis and chemoresistance. (NIH R01CA244413)
    C5.2. NOS/COX2 inhibitors for TNBC.  (Dunn Foundation)
    C5.3. Convergent AI for Precise Breast Cancer Risk Assessment. (NIH R01CA251710)
    C5.4. Digital therapeutics (MOCHA) for post-hospitalization cancer patients and survivors (Chao and Dunn Foundations, Connie Dryer Fund)

  • Alzheimer’s Disease and Related Disorders

    Alzheimer’s Disease and Related Disorders

    N1.  Alzheimer’s Disease Mechanisms and Therapeutics

    N1.1.  Systematic Alzheimer's disease drug repositioning via bioinformatics-guided drug screening and image-omics. (NIH R01AG057635, Margolis Fund)
    N1.2.  Early and late-life metal exposures and Alzheimer’s disease (NIH R01ES024165-S4)
    N1.3.  Systematic modeling and prediction of cell-type-specific and spatiotemporal crosstalk pathways in Alzheimer's disease. (NIH R01AG071496)
    N1.4:  High content screening and analysis for drug repositioning using Alzheimer’s 3D cell assays. (Cure Alzheimer’s Fund, Gillson Longenbaugh Foundation, and Carl Anderson Foundation, Margolis Fund, Steve Cook Fund)
    N1.5:  Gut-brain axis, microbiome-neural interactions in Alzheimer’s disease. (Chao and Dunn Foundations)
    N1.6:  Mitochrondrial dysfunction and OC1AD1 in regulating Alzheimer’s disease progression. (Chao Foundation)
    N1.7:  Reduce risk factors of Alzheimer’s and dementia patients.  (Chao Foundation)
    N1.8:  Multimodal optical coherence tomography probe for detection/monitoring of Alzheimer’s (Chao Foundation)


    N2.  Parkinson’s Disease Mechanisms and Therapeutic

    N2.1:  Drug repositioning for Parkinson’s disease with high content drug screening (Huffington Foundation)


    N3.  Stroke Precision Detection and Diagnosis

    N3.1:  Smart instrumentation for precision assessment of stroke. (Scurlock Foundation; Dunn Foundation)

    N3.2:  Multimedia intelligence for stroke screening and assessment (Scurlock Foundation; Chao Foundation)

  • Label-free Imaging-Guided Theragnostics

    Label-free Imaging-Guided Theragnostics

    M1. Coherent anti-stroke Raman Scattering (CARS) molecular vibrational imaging for early detection of cancer, Alzheimer’s disease, and blast brain injuries. (Chao and Dunn Foundations)

    M2. Dual optical coherent tomography (OCT) and CARS imaging for studying metastatic cancer initiation and progression. (Chao Foundation, Johnsson Estate)

    M3. Label-free imaging-guided cold femtosecond laser single cell microablation. (Chao and Dunn Foundations)

Research Areas

Diseases

  • Solid adult and pediatric tumors
  • Alzheimer’s disease and dementia
  • Stroke
  • Parkinson’s disease and movement disorders
  • Diabetes and related metabolic disorders

Methods and Technologies

  • Artificial Intelligence in Medicine
  • Bioinformatics and Biostatistics
  • Biological and Medical Image Analysis
  • Cancer Biology and Neurobiology
  • Clinical Informatics
  • Digital Health
  • Drug Repositioning and Discovery
  • Internet of Medical Things
  • Neuroimaging
  • Optical Microscopy and Biophotonics
  • Systems Biology

Bioinformatics Software

CCCEXPLORER FOR CANCER
CCCExplorer is a java-based software that predicts and visualizes the gene signaling network to aid research on crosstalk identification in the tumor microenvironment. CCCExplorer integrates a computational model that we developed to uncover cell-cell communication as a direct and connected network. These cell communications range from ligand-receptor interactions to transcription factors and their target genes. Learn more about CCCExplorer software.

Ref:

  1. Yeung TL, Sheng J, Leung CS, Li F, Kim J, Ho SY, Matzuk MM, Lu KH, Wong STC*, Mok SC*. Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer. J Natl Cancer Inst. 2018 May 31. PMID: 29860390.
  2. Choi H, Sheng J, Gao D, Li F, Durrans A, Ryu S, Lee SB, Narula N, Rafii S, Elemento O, Altorki NK, Wong ST*, Mittal V*.  Transcriptome analysis of individual stromal cell populations identifies stroma-tumor crosstalk in mouse lung cancer model. Cell Reports. 2015 Feb 24;10(7):1187-201. PMID: 2570482

DISNEY
Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma.  Medulloblastoma (MB) is the most common malignant brain tumor of childhood. Although outcomes have improved in recent decades, new treatments are still needed to improve survival and reduce treatment-related complications.

DrugComboExplorer
Drug combinations that simultaneously suppress multiple cancer driver signaling pathways increase therapeutic options and may reduce drug resistance. We have developed a computational systems biology tool, DrugComboExplorer, to identify driver signaling pathways and predict synergistic drug combinations by integrating the knowledge embedded in vast amounts of available pharmacogenomics and omics data. Learn more about DrugComboExplorer software.

DrugComboRanker
DrugComboRanker is a computational tool that prioritizes synergistic drug combinations and uncovers their mechanisms of action. Learn more about DrugComboRanker.

G-CelliQ Image Processing Tool
Morphological plasticity is critical to organism development - as exemplified by the reversible conversion of embryonic non-migratory epithelial cells to motile mesenchymal cells required for tissue Morphological plasticity is critical to organism development as exemplified by the reversible conversion of embryonic non-migratory epithelial cells to motile mesenchymal cells required for tissue positioning and organization.

Undergraduate Students, Graduate Students, Staff, and External Collaborators

Graduate Students:

  • Jonathon Cummock, TAMU-MD, PhD Student
  • Rahul Ghosh, MSc, TAMU-MD, PhD Student
  • Daniel Kermany, MSc, TAMU-MD, PhD Student
  • Ju Ahn Young, BSc, TAMU-MD, PhD Student
  • Glori Das, BSc, TAMU-MD, PhD Student
  • Wesley Poon, BSc, TAMU-MD, PhD Student
  • Orhun Davarci, MSc, TAMU EnMed Student
  • Natasha Nehra, BSc, TAMU EnMed Student
  • Gogol Bhattacharya, MSc, TAMU EnMed Student
  • Reid Master, BSc, TAMU EnMed Student
  • Patrick Sui, McGill University, PhD Student
  • Vo Hung, UH, PhD Student
  • Tongan Cao, Penn State University, PhD Student
  • Jihua Liu, Bsc, U Penn, Biostatistics Master Student

Undergraduate Students:

David Hunt, TAMU, Computer Science

Staff

Computational and Informatics Staff:

  • Yuliang Cao, MSc
  • Zhihao Wan, MSc
  • Shiruo Wang, MSc
  • Xiaohui Yu, MSc

Lab Staff:

  • Dongbing Gao, MSc
  • Matthew Vasquez, BSc
  • Shan Xu, MD
  • Michael Chan, BSc
  • Bill Chan, BSc

Administrative Staff:

  • Tian Ding, PhD, MBA
  • Chika Frank Ezeana, MD, MPH
  • Deborah Dowell
  • Martha Silva

External Collaborations:

Clinical Trials

At Houston Methodist, our dedicated teams of world-renowned researchers help support the mission of our Cancer Research of bringing the latest technologies and advanced treatment options to patients as quickly and safely as possible. 

Explore Our Cancer Research Clinical Trials ➝

TOP